Brightline Interactive Requests Hearing Before Nasdaq Hearings Panel to Appeal Nasdaq Staff Determination Letter

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

Florida sued Eli Lilly, Novo Nordisk, and pharmacy benefit managers, alleging they used rebates to maintain high drug prices, harming patients and independent pharmacies. The state claims these practices discouraged competition and limited access to affordable treatments, seeking damages and changes to pricing practices. The case focuses on insulin and GLP-1 medications, with Florida citing significant market power among the defendants.

DoorDash agreed to a $131.5M settlement with NYC, covering 264,000 drivers underpaid or paid late. $115M goes to workers, $16M to penalties. The largest portion resolves a dispute over on-call pay calculation. DoorDash will use NYC's method going forward and will report payments to regulators for 3 years.

ANI Pharmaceuticals (ANIP) received FDA approval for its generic Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product, a generic version of Afinitor Disperz, expands ANI's generics portfolio. The company expects to launch at least 15 new generic products this year. U.S. annual sales for the approved product were approximately $123 million, according to IQVIA data cited by ANI. ANIP's stock closed at $77.91 on Tuesday, with pre-market trading at $78.99.

ExxonMobil's Rose CCS project in Texas received a Class VI injection well permit, marking a milestone for the carbon capture industry. The project could generate billions in regional economic activity. The Gulf Coast is ideal for CCS due to its industrial facilities, CO2 pipeline network, and geology. Louisiana must balance regulation and permitting efficiency to attract CCS investments, according to Scott Castleman of the Gulf Coast CCS Alliance.

Meta agreed to a US$17.1 billion settlement for child-safety issues, requiring changes to Facebook and Instagram. The settlement, while not creating new UK/EU legal obligations, highlights design risks under GDPR, DSA, and UK OSA. It sets a precedent for assessing service architecture and safeguards for minors, impacting global digital businesses.